{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T05:19:54Z","timestamp":1741238394684,"version":"3.38.0"},"reference-count":16,"publisher":"JLE","issue":"6","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T00:00:00Z","timestamp":1664409600000},"content-version":"am","delay-in-days":363,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.nephro.2021.01.004","type":"journal-article","created":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T13:31:54Z","timestamp":1620739914000},"page":"422-427","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prise en charge de l\u2019hyperkali\u00e9mie r\u00e9cidivante et utilisation des inhibiteurs du syst\u00e8me r\u00e9nine-angiotensine-aldost\u00e9rone\u00a0: analyse des donn\u00e9es fran\u00e7aises de l\u2019\u00e9tude multinationale europ\u00e9enne PROKALE"],"prefix":"10.1684","volume":"17","author":[{"given":"Patrick","family":"Rossignol","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18929","reference":[{"key":"10.1016\/j.nephro.2021.01.004_bib0085","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1159\/000479802","article-title":"Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and\/or diabetes","volume":"46","author":"Collins","year":"2017","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.nephro.2021.01.004_bib0090","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10557-017-6767-5","article-title":"New therapeutic approaches for the treatment of hyperkalemia in patients treated with renin-angiotensin-aldosterone system inhibitors","volume":"32","author":"Tamargo","year":"2018","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.nephro.2021.01.004_bib0095","first-page":"1","article-title":"KDIGO 2012\u00a0clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","year":"2013","journal-title":"Kidney Int Suppl"},{"year":"2015","series-title":"Chronic kidney disease in adults: assessment and management. Clinical guideline (CG182)","key":"10.1016\/j.nephro.2021.01.004_bib0100"},{"key":"10.1016\/j.nephro.2021.01.004_bib0105","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2021.01.004_bib0110","doi-asserted-by":"crossref","DOI":"10.1002\/ejhf.1793","article-title":"Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222\u00a0chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry","author":"Rossignol","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.nephro.2021.01.004_bib0115","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1001\/archinternmed.2009.132","article-title":"The frequency of hyperkalemia and its significance in chronic kidney disease","volume":"169","author":"Einhorn","year":"2009","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.nephro.2021.01.004_bib0120","doi-asserted-by":"crossref","first-page":"A48","DOI":"10.1093\/eurheartj\/suy032","article-title":"A new area for the management of hyperkalaemia with potassium binders: clinical use in nephrology","volume":"21","author":"Rossignol","year":"2019","journal-title":"Eur Heart J Suppl"},{"key":"10.1016\/j.nephro.2021.01.004_bib0125","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.amjmed.2015.05.040","article-title":"Management of hyperkalemia: an update for the internist","volume":"128","author":"Kovesdy","year":"2015","journal-title":"Am J Med"},{"key":"10.1016\/j.nephro.2021.01.004_bib0130","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1093\/ckj\/sfz129","article-title":"Recurrent hyperkalaemia management and use of renin-angiotensin-aldosterone system inhibitors: a European multi-national targeted chart review","volume":"13","author":"Rossignol","year":"2020","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.nephro.2021.01.004_bib0135","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1002\/ehf2.12834","article-title":"Hyperkalaemia and hypokalaemia outpatient management: a survey of 500\u00a0French general practitioners","volume":"7","author":"Abensur Vuillaume","year":"2020","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.nephro.2021.01.004_bib0140","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1161\/CIRCULATIONAHA.117.030576","article-title":"Long-term potassium monitoring and dynamics in heart failure and risk of mortality","volume":"137","author":"N\u00fa\u00f1ez","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.nephro.2021.01.004_bib0145","first-page":"1","article-title":"The importance of developing hyperkalaemia in heart failure during long-term follow-up","author":"Martens","year":"2020","journal-title":"Acta Cardiol"},{"key":"10.1016\/j.nephro.2021.01.004_bib0150","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/eurheartj\/ehq502","article-title":"Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial","volume":"32","author":"Pitt","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.nephro.2021.01.004_bib0155","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1410853","article-title":"Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors","volume":"372","author":"Weir","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2021.01.004_bib0080","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(19)32135-X","article-title":"Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial","volume":"394","author":"Agarwal","year":"2019","journal-title":"Lancet"}],"container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725521000572?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725521000572?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.jle.com\/10.1016\/j.nephro.2021.01.004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T14:26:51Z","timestamp":1741184811000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1769725521000572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S1769725521000572"],"URL":"https:\/\/doi.org\/10.1016\/j.nephro.2021.01.004","relation":{},"ISSN":["1769-7255"],"issn-type":[{"type":"print","value":"1769-7255"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prise en charge de l\u2019hyperkali\u00e9mie r\u00e9cidivante et utilisation des inhibiteurs du syst\u00e8me r\u00e9nine-angiotensine-aldost\u00e9rone\u00a0: analyse des donn\u00e9es fran\u00e7aises de l\u2019\u00e9tude multinationale europ\u00e9enne PROKALE","name":"articletitle","label":"Article Title"},{"value":"N\u00e9phrologie & Th\u00e9rapeutique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nephro.2021.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 francophone de n\u00e9phrologie, dialyse et transplantation.","name":"copyright","label":"Copyright"}]}}